Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy

Ella C. Berry,* Sean Mullany,* Alannah Quinlivan† Amelia Craig,* Julia New-Tolley,‡ James Slattery,* Shawgi Sukumaran,§ Sonja Klebe,§ Jamie E. Craig,* Owen M. Siggs,†∥ and Mihir D. Wechalekar†

Summary: Immune checkpoint inhibitor therapy is frequently associated with immune-related adverse events, which occasionally manifest with visual symptoms. Here, we describe a case of unilateral and sudden-onset painless vision loss in an 82-year-old man with metastatic non–small cell lung cancer receiving immunotherapy with the anti-programmed death-ligand 1 agent atezolizumab. Examination demonstrated a right-sided relative afferent pupillary defect, diffusely swollen optic disc, and delayed choroidal and retinal arterial filling on fundus fluorescein angiography, consistent with an arteritic anterior ischemic optic neuropathy. Histology of an ipsilateral temporal artery biopsy revealed a transmural eosinophilic infiltrate without granulomas, while serology revealed the presence of antineutrophil cytoplasmic antibodies. Peripheral eosinophilia was also noted, which preceded treatment by several months. This report highlights the importance of clinician awareness of immune checkpoint inhibitors and their systemic and ophthalmic complications, which rarely appear to extend to eosinophilic temporal arteritis.

Key Words: eosinophilic vasculitis, temporal arteritis, anterior ischemic optic neuropathy, immunotherapy, immune checkpoint inhibitor, programmed cell death 1, PD-L1, atezolizumab

(J Immunother 2022;45:51–55)

CASE PRESENTATION

An 82-year-old man of European ancestry with a history of metastatic non–small cell lung adenocarcinoma presented to the emergency department of a tertiary medical centre complaining of a 1-week history of sudden-onset painless vision loss in the right eye and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication. On examination, his best-corrected visual acuity was no light perception and a 5-week history of frontal headaches and jaw claudication.

Received for publication May 5, 2021; accepted August 27, 2021.
From the Departments of *Ophthalmology; †Rheumatology; ‡Oncology; §Pathology, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA; and †Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. E.C.B., S.M., and A.Q. are joint first authors. O.M.S. and M.D.W. are joint senior authors.
Reprints: Ella C. Berry, Department of Ophthalmology, 1 Flinders Drive, Bedford Park 5042, SA, Australia (e-mail: ella.c.berry@gmail.com).
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

J Immunother • Volume 45, Number 1, January 2022 www.immunotherapy-journal.com | 51
FIGURE 1. Unilateral optic nerve head swelling and retinal ischemia. Retinal photography of the right fundus demonstrated a swollen, pale optic nerve head, with generalized retinal ischemia evidenced by cotton wool spots and a “cherry-red spot” within the fovea (A). The left fundus by contrast was grossly normal (B). Optic nerve head spectral-domain optical coherence tomography (SD-OCT) imaging of the right eye demonstrated predominantly nasal optic nerve head swelling evident in horizontal cross-section and 3-dimensional projection (C). Left optic nerve head SD-OCT images were unremarkable (D). Horizontal cross-sectional SD-OCT imaging of the right fovea demonstrated hyperreflectivity of the inner retinal layers, characteristic of retinal ischemia (E). SD-OCT imaging of the left fovea, by comparison, was unremarkable (F). Representative fundus fluorescein angiography imaging of the right eye demonstrated profoundly delayed arterial perfusion with patchy choroidal perfusion at 0:55 minutes (G). Retinal arterial perfusion was first observed at 1:50 minutes, with venous and incomplete choroidal perfusion observed at 5:03 minutes (H). Fundus fluorescein angiography imaging of the left eye demonstrated normal arterial, venous, and choroidal perfusion at similar time points of 1:28 and 5:22 minutes following intravenous fluorescein bolus infusion (I). LE indicates left eye; RE, right eye.
The diagnosis was revised to an antineutrophil cytoplasmic antibody–positive eosinophilic vasculitis affecting temporal arteries. Following a multidisciplinary case review, atezolizumab was discontinued, and he was commenced on 10 mg oral methotrexate weekly in addition to 1 mg/kg oral prednisolone. Furthermore, the patient was commenced on trimethoprim and sulfamethoxazole for pulmonary pneumocystis jiroveci prophylaxis and omeprazole for gastric ulcer prophylaxis. Three weeks later, he presented to the emergency department with shortness of breath and fever. He was diagnosed with pneumonia which was managed palliatively. He died 2 days later.

**DISCUSSION**

We describe a case of sudden-onset vision loss in a man undergoing treatment with the immune checkpoint inhibitor (ICI) atezolizumab (a PD-L1 inhibitor), associated with an eosinophilic temporal arteritis and a unilateral AAION. To our knowledge, this is the first study to provide histopathologic evidence of eosinophilic vasculitis occurring in the context of ICI therapy. In addition, this is the first documented case of an AAION in a patient undergoing anti-PD-L1 therapy.

ICIs are a novel class of monoclonal antibodies used for the treatment of cancer. Collectively, these drugs function by stimulating antitumor immunity through the disinhibition of T cells via cell surface proteins including programmed cell death protein 1 (PD-1), PD-L1, and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4). Though these drugs are typically second or third-line therapeutics for the treatment of various metastatic diseases, their use has revolutionized cancer medicine.1

These therapies have been recognized to result in various immune-related adverse events (irAEs). Accordingly, there is a need for vigilant pharmacosurveillance to determine the nature and frequency of adverse events. As a presumed consequence of T-cell disinhibition, ICIs appear to upregulate various autoimmune processes. The mechanisms by which these processes occur, however, remain to be elucidated.2,3 Evidence suggests that 20%–39% of patients undergoing immunotherapy with anti-PD-1 and anti-PD-L1 inhibitors experience 1 or more irAEs.4 The most commonly affected sites are the endocrine, dermatologic, and gastrointestinal systems. PD-L1 inhibitors have been associated with a slightly lower incidence of irAEs than PD-1 inhibitors, potentially due to the fact that PD-1 inhibition prevents engagement of both PD-L1 and PD-L2 with PD-1, while PD-L1 inhibition prevents only the engagement of PD-L1 with PD-1.4

Though ICI-associated vasculitis is uncommon, it appears to predominantly affect large vessels, resulting in large vessel vasculitis including giant cell arteritis, aortitis, and primary angiitis of the nervous system.3,5 Most cases of ICI-associated vasculitis have been reported with PD-1 or CTLA-4 inhibitor therapy.5 AAION is a consequence of vessel wall inflammation resulting in occlusion of arteries supplying the eye. The most common cause of AAION is giant cell arteritis. Eosinophilic vasculitis by contrast, is a rare cause of AAION.5 We are aware of 6 cases of AAION reported in the context of ICI therapy, each of which involved either a CTLA-4 inhibitor or a PD-1 inhibitor.6,8 A single case of eosinophilic granulomatosis with polyangiitis has been reported previously in a patient undergoing PD-L1 inhibitor therapy. Unfortunately, this association was confounded by concurrent anti-CTLA-4 therapy, and no histopathologic specimens were available to confirm the presence of vasculitis.5

A salient feature of the current case is the retrospective observation of peripheral eosinophilia preceding initiation of therapy by at least 9 months (Fig. 3). Eosinophilia has been observed in cancer patients treated with ICIs9 and is thought by some to be a biomarker of treatment success.10 The PD-1 pathway is intimately involved in the regulation of type 2 innate lymphoid cells (ILC2) in which it acts as a metabolic checkpoint;
activated ILC2s secrete high amounts of Th2 cytokines including interleukin 5, a specific and potent activator of eosinophils. PD-1 agonism ameliorates ILC2 activation. While formal cytokine studies were not undertaken in this patient, it is conceivable that activation of the PD-1/PD-L1 pathway by atezolizumab led to ILC2 (and thus interleukin 5) mediated eosinophil activation, the scene being set for this with his background eosinophilia. Eosinophilia is not a current contraindication to PD-L1 therapy. We do, however, question its pathoetiological relevance in a patient who subsequently developed an eosinophilic vasculitis after commencing ICI therapy.

This study highlights a unique presentation of vision loss resulting from an AAION associated with eosinophilic temporal arteritis in a patient undergoing treatment with the PD-L1 inhibitor atezolizumab. Although this appears to be the first reported case of eosinophilic temporal arteritis associated with ICI therapy, it is unclear if this therapy was a precipitant since eosinophilia predated the commencement of treatment. Nonetheless, with the increasing use of these therapies, and concomitant increase in the number of irAEs, physicians and ophthalmologists alike should be aware of the association and its potential severe visual consequences.

ACKNOWLEDGMENTS

The authors thank Angela Chappell and Carly Emerson (Flinders Medical Centre) for ophthalmic images.

Conflicts of Interest/Financial Disclosures

None reported. All authors have declared that there are no financial conflicts of interest with regard to this work.

REFERENCES

1. Xin Yu J, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18:899–900.
2. Xu C, Chen Y-P, Du X-J, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.

FIGURE 3. Peripheral eosinophilia predating atezolizumab therapy. Peripheral eosinophilia had been evident for a period of 9 months before commencing of atezolizumab therapy. Before 2019, and in the context of chemotherapy, peripheral eosinophil concentrations were within the normal range. Elevated levels were observed after completion of pemetrexed therapy, and during atezolizumab therapy (A). Normal range eosinophils were subsequently seen in the context of corticosteroid therapy (B). NSCLC indicates nonsmall cell lung cancer.
3. Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors—a systematic review. *Clin Rheumatol*. 2018;37:2579–2584.
4. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-1I inhibitors in non-small cell lung cancer: a systematic analysis of the literature. *Cancer*. 2018;124:271–277.
5. Roger A, Groh M, Lorillon G, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. *Ann Rheum Dis*. 2019;78:e82.
6. Salem J-E, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. *Lancet Oncol*. 2018;19:1579–1589.
7. Padovano I, Pazzola G, Pipitone N, et al. Anterior ischaemic optic neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a case report and review of the literature. *Clin Exp Rheumatol*. 2014;32:S62–S65.
8. Mukharesh L, Chwalisz BK. Neuro-ophthalmic complications of immune-checkpoint inhibitors. *Semin Ophthalmol*. 2021;36:241–249.
9. Scanvion Q, Béné J, Gautier S, et al. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. *Oncoimmunology*. 2020;9:1722022.
10. Simon SCS, Hu X, Panten J, et al. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. *Oncoimmunology*. 2020;9:1727116.